Shares of GPC Biotech
GPC's lead drug is the oral chemotherapy agent Satraplatin. To date, the compound has been tested in more than 1,500 patients in its clinical trials. In a pivotal phase 3 study as a treatment for late-stage prostate cancer, Satraplatin produced statistically significant improvements in rates of progression-free survival versus non-Satraplatin treated patients.
Due to the highly positive efficacy results with the drug and the FDA's historical actions, I believe Satraplatin will become the first late-stage prostate cancer treatment since the agency approved Sanofi-Aventis'
GPC is also testing Satraplatin in other indications like non-small cell lung cancer (NSCLC), but it might not be long until on- and off-label competition from other oral chemotherapeutics arrives. Two weeks ago, GlaxoSmithKline
The other upcoming risk for GPC involves an arbitration panel hearing in July with Spectrum Pharmaceuticals
GPC's market cap is less than a billion dollars. With a novel cancer compound that should be on the market by the end of the year, and full U.S. marketing rights to Satraplatin, GPC deserves a look from investors in search of the next new cancer treatment to gain regulatory approval.
Looking for more Foolish drug stock coverage? Check out the Fool's market-beating Rule Breakers newsletter. You can see all our recommendations as well as get access to our message boards and exclusive content with a 30-day free trial.